3 withdrawn. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Withdrawn 3 |
Follow Refractory Marginal Zone Lymphoma: new trials by email Literature Review of Refractory Marginal Zone Lymphoma trials Research Report on Refractory Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Acalabrutinib, Duvelisib - Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 1 | Withdrawn | Narendranath Epperla | 2022-07-01 | 2022-06-07 | |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2021-07-27 | 2024-04-25 |
Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Follicular (3) · Lymphoma, B-Cell (2) · Lymphoma, Mantle-Cell (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Hematologic Diseases (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Hemorrhagic Disorders (1)
CPG-oligonucleotide (1) · LFB-R603 (1) · Lenalidomide (1) · Radiation (1) · Radiotherapy (1) · acalabrutinib (1) · duvelisib (1) · ublituximab (1) · umbralisib (1)
City of Hope Medical Center (1) · Narendranath Epperla (1) · Yazeed Sawalha (1)
Lihua E Budde (1) · Narendranath Epperla, MD (1) · Yazeed Sawalha, MD (1)
P30CA033572 (1), P50CA107399 (1)